Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose intravenous perampanel to prevent early postoperative seizures after brain tumor surgery (poSTOP seizure-2 BT)
jRCTs031240687Recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Mar 2025
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Single-arm trial of perampanel in seizure and brain neoplasm, sponsored by Eisai Co., Ltd. Primary endpoint: Incidence of early postoperative seizures within 7 days after surgery. Started Mar 2025; status: recruiting.
02
Drugs
perampanel
03
Conditions
seizurebrain neoplasm
Beyond the preview
Go deeper on jRCTs031240687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240687.